Rahul Banerjee: AURIGA results in IMS 2024 app
Rahul Banerjee shared a post on X:
”AURIGA results in the International Myeloma Society (IMS) 2024 app!
After autologous stem cell transplant (ASCT) in multiple myeloma (MM), 30-month progression-free survival (PFS) was 83% with daratumumab and lenalidomide (Dara-R) versus 66% with lenalidomide (R) alone.
Can’t directly extrapolate to quad induction or MRD- after ASCT, and not powered for PFS…
… but as a previously loud cynic of CD38-R maintenance sans RCT data, I am a changed man.”
Source: Rahul Banerjee/X
Rahul Banerjee is an assistant professor at Fred Hutchinson Cancer Center at the University of Washington. He completed his residency from the University of Pennsylvania health system. He completed his fellowship in hematology and oncology from University of California, San Francisco. He has authored over 70-peer reviewed publications. His clinical interests include multiple myeloma.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023